Europe Erythropoietin Market by Product Type (Epoetin-Alfa, Epoetin-Beta and Others), Drug Class (Biologics, and Biosimilar), Indication (Cancer, Hematology, Renal Diseases, Neurology) and By Country - Global Forecast to 2030
MarketResearch.biz announces publication of its most recently generated research report titled, “Europe Erythropoietin Market by Product Type (Epoetin-Alfa, Epoetin-Beta, Darbepoetin-Alfa, Other Product Types), Drug Class (Biologics, and Biosimilar), Indication (Cancer, Hematology, Renal Diseases, Neurology) and Country (Germany, UK, France, Italy, Spain, Russia, Rest of Europe) - Europe Forecast to 2030.”, which offers a holistic view of the Europe erythropoietin market through systematic segmentation that covers every aspect of the target market. The Europe Erythropoietin market is projected to be US$ 2,456.9 Mn in 2021 to reach US$ 5,432.3 Mn by 2030 at a CAGR of 8.4%.
Erythropoietin (EPO) is a hormone that is produced primarily by the kidneys, with small amounts created by the liver. Erythropoietin is an essential protein hormone that red blood cells (erythrocytes) produce. The red blood cells themselves transport oxygen to all bodily tissues. This hormone is synthesized in the kidneys, and its secretion is regulated by the amount of oxygen delivered to an organ. Erythropoietin is one of the first drugs produced through recombinant DNA technology, and is widely used in situations where the production of red blood cells is insufficient. Erythropoietin is essential for the production of red blood cells because it is necessary for the survival, proliferation and differentiation of erythroid progenitor cells in bone marrow. In the late stage of red blood cell differentiation, the receptor of erythropoietin is down-regulated, with the hormone being no longer necessary for a cell’s survival.
Europe Erythropoietin Market Revenue (US$ Mn), 2021–2030The rising prevalence of cancer, ESRD (end-stage renal disease) and HIV has largely contributed to the increase in the demand for EPO drugs. Approximately 20% of cancer/HIV patients and approximately 70% of ESRD patients receive chemotherapy, which usually leads to anemia in such patients and therefore requires appropriate EPO treatment. This is the main revenue-generating factor in the erythropoietin market. The expiration of patents for major biological agents over the next few years will create opportunities for erythropoietin biosimilars to enter the market. For example, Amgen's Epogen patent expired in 2018, which provided a huge opportunity for other companies to enter the erythropoietin industry. Hence, it is expected that there will be an increase in the number of new entrants investing in this sector, resulting in subsequent revenue growth.
The outbreak of the COVID-19 pandemic has severely affected various manufacturing and supply chain operations in various industries including the healthcare industry. Most erythropoietin drug manufacturers stated that the temporarily interrupted drug supply subsequently led to a slowdown/suspension of the corresponding business, which had a negative impact on the industry.
Europe Erythropoietin Market Attractiveness Analysis by Form, 2014–2030By country, the market is segmented into Germany, UK, France, Italy, Spain, Russia, Rest of Europe. Based on region, On the basis of country, the markets in Germany are projected to continue to account for the majority revenue share of the erythropoietin market in Europe.
The research report on the Europe erythropoietin market includes profiles of some of the major companies such as Johnson & Johnson, Roche Holding AG, Pfizer Inc. (Hospira), Amgen, Inc, Kirin Holdings Co., Ltd. (Kyowa Hakko Kirin), Teva Pharmaceutical Industries Ltd, LG Corp. (LG Life Sciences Ltd.), Intas Pharmaceuticals Ltd, Biocon Ltd., Emcure Pharmaceuticals.
Europe Erythropoietin Market Segmentation Based on Product Type, Drug Class, Indication, and Country
Based on Product Type
- Other Product Types
Based on Drug Class
Based on Indication
- Renal Diseases
Based on Country
- Rest of Europe
- Johnson & Johnson
- Roche Holding AG
- Pfizer Inc. (Hospira)
- Kirin Holdings Co.
- Ltd. (Kyowa Hakko Kirin)
- Teva Pharmaceutical Industries Ltd
- LG Corp. (LG Life Sciences Ltd.)
- Intas Pharmaceuticals Ltd
- Biocon Ltd.
- Emcure Pharmaceuticals.
Don't just take our word. We are trusted by these great companies!